Epacadostat is under clinical development by Incyte and currently in Phase II for Rectal Cancer. According to GlobalData, Phase II drugs for Rectal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Epacadostat LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epacadostat overview

Epacadostat (INCB-24360) is under development for the treatment of non-small cell lung cancer, urothelial carcinoma, rectal cancer and recurrent glioblastoma multiforme, epstein-barr virus positive (EBV+) nasopharyngeal carcinoma and salivary gland cancer. It is a small molecule administered orally as a tablet and targets indoleamine-2, 3-dioxygenase-1 (IDO1).

It was under development for epithelial ovarian cancer, ocular melanoma, metastatic melanoma, primary peritoneal carcinoma, fallopian tube cancer, thymic carcinoma, metastatic renal cell carcinoma, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, metastatic urothelial cancer, recurrent head and neck cancer squamous cell carcinoma, ocular melanoma, colorectal cancer, ovarian cancer, diffuse large B-cell lymphoma, breast cancer, adenocarcinoma of endometrial cancer, B-cell Hodgkin, non-hodgkin lymphoma, pancreatic cancer, endometrial cancer, renal cell carcinoma, hepatocellular carcinoma and gastric cancer, myelodysplastic syndrome.

Incyte overview

Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

For a complete picture of Epacadostat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.